158 related articles for article (PubMed ID: 16175615)
1. New kinetic models for the hepatitis C virus.
Perelson AS; Herrmann E; Micol F; Zeuzem S
Hepatology; 2005 Oct; 42(4):749-54. PubMed ID: 16175615
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modeling of HCV infection and treatment.
Dahari H; Shudo E; Ribeiro RM; Perelson AS
Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
[TBL] [Abstract][Full Text] [Related]
3. Current and future concepts in hepatitis C therapy.
Pawlotsky JM
Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
[TBL] [Abstract][Full Text] [Related]
4. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
5. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
6. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood.
Müller V; Marée AF; De Boer RJ
J Virol; 2001 Mar; 75(6):2597-603. PubMed ID: 11222682
[TBL] [Abstract][Full Text] [Related]
7. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
9. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
10. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
11. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
13. Treatment and vaccination for hepatitis C: present and future.
Jawaid A; Khuwaja AK
J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus: prospects for future therapies.
Wilkinson T
Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
16. Treatment predictors of a sustained virologic response in hepatitis B and C.
Kau A; Vermehren J; Sarrazin C
J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
[TBL] [Abstract][Full Text] [Related]
17. Acute hepatitis C: prevention and treatment.
Ozaras R; Tahan V
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis C-virus --virus kinetics and resistance mechanisms].
Herrmann E; Sarrazin C
Z Gastroenterol; 2004 May; 42(5):387-96. PubMed ID: 15136939
[TBL] [Abstract][Full Text] [Related]
19. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
20. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
